Literature DB >> 21681787

Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD.

Harshabad Singh1, Lillian L Werner, Salma Asali, Daniel J DeAngelo, Karen K Ballen, Philip C Amrein, Martha Wadleigh, Ilene Galinsky, Brian Wolpin, Joseph Pidala, Donna S Neuberg, Edward A Fox, Richard M Stone, Eyal C Attar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21681787      PMCID： PMC3495174          DOI： 10.1002/ajh.22041

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  27 in total

1.  Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML.

Authors:  Martin Bornhäuser; Thomas Illmer; Markus Schaich; Silke Soucek; Gerhard Ehninger; Christian Thiede
Journal:  Blood       Date:  2007-03-01       Impact factor: 22.113

2.  Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.

Authors:  Ulrike Bacher; Claudia Haferlach; Wolfgang Kern; Torsten Haferlach; Susanne Schnittger
Journal:  Blood       Date:  2007-10-26       Impact factor: 22.113

3.  FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation.

Authors:  G Yoshimoto; K Nagafuji; T Miyamoto; N Kinukawa; K Takase; T Eto; K Kato; S Hayashi; T Kamimura; Y Ohno; S Taniguchi; M Harada
Journal:  Bone Marrow Transplant       Date:  2005-12       Impact factor: 5.483

Review 4.  Mutant FLT3 signaling contributes to a block in myeloid differentiation.

Authors:  Rui Zheng; Donald Small
Journal:  Leuk Lymphoma       Date:  2005-12

Review 5.  Acute myeloid leukaemia.

Authors:  Elihu Estey; Hartmut Döhner
Journal:  Lancet       Date:  2006-11-25       Impact factor: 79.321

6.  Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT).

Authors:  M Doubek; J Muzík; T Szotkowski; V Koza; P Cetkovský; T Kozák; P Zák; J Voglová; S Struncová; L Dusek; K Indrák
Journal:  Neoplasma       Date:  2007       Impact factor: 2.575

7.  FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).

Authors:  Ksenia Bagrintseva; Stefanie Geisenhof; Ruth Kern; Sabine Eichenlaub; Carola Reindl; Joachim W Ellwart; Wolfgang Hiddemann; Karsten Spiekermann
Journal:  Blood       Date:  2004-12-30       Impact factor: 22.113

8.  Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.

Authors:  Sabine Kayser; Richard F Schlenk; Martina Correa Londono; Frank Breitenbuecher; Kerstin Wittke; Juan Du; Silja Groner; Daniela Späth; Jürgen Krauter; Arnold Ganser; Hartmut Döhner; Thomas Fischer; Konstanze Döhner
Journal:  Blood       Date:  2009-07-14       Impact factor: 22.113

9.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Authors:  Rosemary E Gale; Claire Green; Christopher Allen; Adam J Mead; Alan K Burnett; Robert K Hills; David C Linch
Journal:  Blood       Date:  2007-10-23       Impact factor: 22.113

Review 10.  Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.

Authors:  Tara K Gregory; David Wald; Yichu Chen; Johanna M Vermaat; Yin Xiong; William Tse
Journal:  J Hematol Oncol       Date:  2009-06-02       Impact factor: 17.388
View more
  2 in total

1.  Treatment of FLT3-ITD acute myeloid leukemia.

Authors:  Amir T Fathi; Yi-Bin Chen
Journal:  Am J Blood Res       Date:  2011-09-09

2.  High-dose idarubicin plus busulfan as conditioning regimen to autologous stem cell transplantation: promising post-remission therapy for acute myeloid leukemia in first complete remission?

Authors:  Ming Hong; Kou-Rong Miao; Run Zhang; Hua Lu; Peng Liu; Wei Xu; Li-Juan Chen; Su-Jiang Zhang; Han-Xin Wu; Hong-Xia Qiu; Jian-Yong Li; Si-Xuan Qian
Journal:  Med Oncol       Date:  2014-05-07       Impact factor: 3.064
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.